AltaIR Capital

AltaIR Capital is a US-based generalist early-stage venture firm with a multi-fund track record across software, marketplaces, fintech, and selective healthcare investments. The firm has historically had ties to founders out of Eastern Europe and Israel and operates as a typical seed-to-Series-A fund with global reach. Healthcare is not the headline thesis, but they have made digital health and health-IT investments where the business looks like a fast-growing software company with a US commercial footprint. Stage focus is seed through Series A, with check sizes plausibly $500K to $3M and a willingness to follow on into Series B in winners. Founders who should approach: software-led digital health companies with strong early traction, founders with prior exits or operator credibility, and teams selling into US providers, payers, or employers with a SaaS or transactional model. Founders who should not approach: regulated devices, biotech, and clinical AI requiring deep domain co-investors that AltaIR is unlikely to syndicate. The fund’s value-add tilts toward go-to-market, GTM hiring, and downstream investor introductions rather than clinical or regulatory expertise. Entry path is warm introduction from a portfolio founder; AltaIR is responsive when the founder pedigree is strong and the metrics are clearly above benchmark. LinkedIn outreach to specific partners is reasonable as a secondary path. Founders should be prepared to discuss customer concentration, sales efficiency, and net retention — AltaIR’s diligence runs the standard SaaS playbook regardless of healthcare framing.